24/7 Market News Snapshot 06 February, 2025 – Relmada Therapeutics, Inc. Common Stock (NASDAQ:RLMD)

February 6, 2025

DENVER, Colo., 06 February, 2025 (247marketnews.com) – (Nasdaq:RLMD) are discussed in this article.
Relmada Therapeutics, Inc. (Nasdaq:RLMD) is witnessing a notable surge in its stock price, currently trading at $0.502, representing a significant 32.1% increase from the previous day’s close. This remarkable rise is accompanied by a robust trading volume of 9.09 million shares, reflecting strong investor interest and confidence in the company’s future prospects. The current bullish trend has sparked considerable attention among traders, who are closely monitoring RLMD’s developments as the momentum builds.

In a strategic move to enhance its portfolio, Relmada recently announced its acquisition of Sepranolone, a novel neurosteroid initially developed by Asarina Pharma AB. This acquisition positions the company to advance therapeutic options for Tourette syndrome (TS) and other compulsive disorders, with plans to initiate Phase 2b clinical development. Sepranolone is characterized as a first-in-class GABAA Modulating Steroid Antagonist (GAMSA) designed to specifically target the GABAA pathway, counteracting the effects of Allopregnanolone, a neurosteroid associated with the condition.

Data from earlier Phase 2a clinical trials have demonstrated Sepranolone’s ability to significantly reduce tic severity and improve the quality of life for patients while maintaining a favorable safety profile devoid of central nervous system off-target effects. Sergio Traversa, CEO of Relmada, expressed optimism about the acquisition, emphasizing that Sepranolone fits well with the company’s mission to develop effective solutions for challenging central nervous system disorders.

As the demand for better therapeutic alternatives escalates, Relmada’s acquisition of Sepranolone signifies a commitment to pioneering innovative approaches in treating Tourette syndrome. The company plans to provide further updates on Sepranolone’s clinical development as it progresses through 2023, marking a pivotal expansion of its therapeutic offerings.

Related news for (RLMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.